Hjem
Produkter og løsninger innen bildediagnostikk
Molekylær avbildning
PET/CT Scanners
Biograph PET/CT family for radiation therapy planning

Biograph family for
radiation therapy planningSetting the standard in PET/CT for RT

The entire Biograph PET/CT family supports dedicated solutions for radiation therapy planning (RTP) and gives you access to intelligent imaging applications powered by artificial intelligence (AI)-driving the right planning for the right treatment.

Features & Benefits

Setting the standard in PET/CT for RT

Our Biograph PET/CT family offers RT editions with dedicated tools for precise therapy planning that let you deliver exceptional care with diagnostic confidence.

High-performance detectors allow optimized doses and shorter scan times,¹ while intuitive workflow features allow more time with patients and facilitate a comfortable scan experience.

RTP pallet
TG-66-compliant patient table
HD FoV Pro
DirectDensity²
iMAR

PET/CT respiratory gating
FAST 4D²
Phase-matched gating
DirectBreathhold^2,3

AI-enabled intelligent imaging

The Biograph family uses intelligent imaging applications to transform complex procedures and make standardized protocols and personalized scans possible.

Learn more about AIDAN

Clinical decision making

Molecular imaging can help answer clinical questions that might not be answered using anatomical imaging alone. PET/CT provides a combination of metabolic and morphological information, which has a major impact on evaluation and therapy planning of primary and recurrent tumors.

The Biograph family offers an integrated workflow, enabled by syngo.via,⁴ that supports clinical decisions along with a multi-modality tool for deformable registration, dose visualization, beam placement, and more.

Learn more about syngo.via for MI

Clinical use

Clincal image review

Data courtesy of Wentworth-Douglas Hospital, Dover, New Hampshire, USA.

Ultra‑fast TOF (time of flight) for RT precision

Sharp PET images and high contrast to define target volumes with maximum confidence
Ultra‑fast TOF opens a new dimension in PET imaging, especially for RT planning, by enhancing image sharpness, contrast, and overall reliability—even in the most demanding clinical situations
The result is a precise visualization of tumor volumes, more confident segmentation, and better‑informed RT planning. With next‑generation TOF performance, PET becomes a strategic asset to optimize therapeutic decisions

Data courtesy of Wentworth-Douglas Hospital, Dover, New Hampshire, USA.

PET/CT-based target and organ-at-risk delineation for RTP

¹⁸F - PSMA PET/CT - based rendering of a primary tumor volume for radiation therapy planning
The radiation therapy plan was altered in order to include the solitary presacral node in the gross tumor volume (GTV)
Total dose prescribed was 54 Gy to GTV at 1.8 Gy per fraction with dose escalation to the area with highest tracer uptake

Biograph Trinion EP CT64

Data courtesy of Rome Imaging Center, Rome, Georgia, USA.

Esophageal cancer delineation on PET/CT for RTP

¹⁸F - FDG PET/CT - based delineation of a primary lower esophageal carcinoma for radiation therapy planning
Tumor volume is segmented for RT target volume (VOI) generation, followed by radiation therapy structure creation with non‑uniform margins for CTV and
Organ-at-risk segmentation includes lung, heart, aorta, and spinal cord, performed using syngo.via MM RT Image Suite.

Biograph Trinion EP CT64

Data courtesy of Rigshospital Copenhagen Denmark.

Head-and-neck cancer target delineation on PET/CT for RTP

¹⁸F - FDG PET/CT–based delineation of a primary pharyngeal carcinoma with involved cervical lymph nodes for radiation therapy planning
Target volumes are generated from fused PET/CT images acquired in treatment position using immobilization tools
Radiation therapy structures are created with additional margins for PTV, along with organ‑at‑risk segmentation including spinal cord and salivary glands using syngo.via MM RT Image Suite

Biograph Vision 600

Data courtesy of Rome Imaging Center, Rome, Georgia, USA.

Lung cancer delineation on PET/CT for RTP

Primary lung carcinoma in the posterior right lobe with upper paratracheal lymph node metastases delineated on ¹⁸F - FDG PET/CT
Target volumes are generated using a visually adapted threshold approach, with radiation therapy structures created using additional margins for CTV and PTV, accounting for minor respiratory moti
Organ‑at‑risk segmentation includes lung, heart, esophagus, trachea, and spinal cord using syngo.via MM RT Image Suite.

Biograph Trinion EP CT64

Data courtesy of Rigshospital Copenhagen Denmark.

Glioma target delineation on PET/CT for RTP

¹⁸F - FDG PET/CT – guided delineation of recurrent glioma for radiation therapy target volume definition
Viable tumor tissue adjacent to cystic surgical sequelae is identified, with RT target volumes delineated using a defined SUV‑based threshold
GTV and PTV structures are generated with additional margins for radiation therapy planning

Biograph Vision 600

Data courtesy of Wentworth-Douglas Hospital, Dover, New Hampshire, USA.

Ultra‑fast TOF (time of flight) for RT precision

Sharp PET images and high contrast to define target volumes with maximum confidence
Ultra‑fast TOF opens a new dimension in PET imaging, especially for RT planning, by enhancing image sharpness, contrast, and overall reliability—even in the most demanding clinical situations
The result is a precise visualization of tumor volumes, more confident segmentation, and better‑informed RT planning. With next‑generation TOF performance, PET becomes a strategic asset to optimize therapeutic decisions

Data courtesy of Wentworth-Douglas Hospital, Dover, New Hampshire, USA.

PET/CT-based target and organ-at-risk delineation for RTP

¹⁸F - PSMA PET/CT - based rendering of a primary tumor volume for radiation therapy planning
The radiation therapy plan was altered in order to include the solitary presacral node in the gross tumor volume (GTV)
Total dose prescribed was 54 Gy to GTV at 1.8 Gy per fraction with dose escalation to the area with highest tracer uptake

Biograph Trinion EP CT64

Data courtesy of Rome Imaging Center, Rome, Georgia, USA.

Esophageal cancer delineation on PET/CT for RTP

¹⁸F - FDG PET/CT - based delineation of a primary lower esophageal carcinoma for radiation therapy planning
Tumor volume is segmented for RT target volume (VOI) generation, followed by radiation therapy structure creation with non‑uniform margins for CTV and
Organ-at-risk segmentation includes lung, heart, aorta, and spinal cord, performed using syngo.via MM RT Image Suite.

Biograph Trinion EP CT64

Data courtesy of Rigshospital Copenhagen Denmark.

Head-and-neck cancer target delineation on PET/CT for RTP

¹⁸F - FDG PET/CT–based delineation of a primary pharyngeal carcinoma with involved cervical lymph nodes for radiation therapy planning
Target volumes are generated from fused PET/CT images acquired in treatment position using immobilization tools
Radiation therapy structures are created with additional margins for PTV, along with organ‑at‑risk segmentation including spinal cord and salivary glands using syngo.via MM RT Image Suite

Biograph Vision 600

Data courtesy of Rome Imaging Center, Rome, Georgia, USA.

Lung cancer delineation on PET/CT for RTP

Primary lung carcinoma in the posterior right lobe with upper paratracheal lymph node metastases delineated on ¹⁸F - FDG PET/CT
Target volumes are generated using a visually adapted threshold approach, with radiation therapy structures created using additional margins for CTV and PTV, accounting for minor respiratory moti
Organ‑at‑risk segmentation includes lung, heart, esophagus, trachea, and spinal cord using syngo.via MM RT Image Suite.

Biograph Trinion EP CT64

Data courtesy of Rigshospital Copenhagen Denmark.

Glioma target delineation on PET/CT for RTP

¹⁸F - FDG PET/CT – guided delineation of recurrent glioma for radiation therapy target volume definition
Viable tumor tissue adjacent to cystic surgical sequelae is identified, with RT target volumes delineated using a defined SUV‑based threshold
GTV and PTV structures are generated with additional margins for radiation therapy planning

Biograph Vision 600

Data courtesy of Wentworth-Douglas Hospital, Dover, New Hampshire, USA.

Ultra‑fast TOF (time of flight) for RT precision

Sharp PET images and high contrast to define target volumes with maximum confidence
Ultra‑fast TOF opens a new dimension in PET imaging, especially for RT planning, by enhancing image sharpness, contrast, and overall reliability—even in the most demanding clinical situations
The result is a precise visualization of tumor volumes, more confident segmentation, and better‑informed RT planning. With next‑generation TOF performance, PET becomes a strategic asset to optimize therapeutic decisions

The outcomes achieved by the Siemens Healthineers customers described herein were achieved in the customer’s unique setting. Since there is no “typical” hospital and many variables exist (eg, hospital size, case mix, level of IT adoption) there can be no guarantee that others will achieve the same results.

Please see Indications and Important Safety Information for Fludeoxyglucose F 18 (¹⁸F FDG) Injection and full Prescribing Information.

Indications and usage

Fludeoxyglucose F 18 Injection (18F FDG) is indicated for positron emission tomography (PET) imaging in the following settings:

Oncology: For assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer.
Cardiology: For the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function in patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging.
Neurology: For the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures.

Important safety information

Radiation Risk: Radiation-emitting products, including Fludeoxyglucose F 18 Injection, may increase the risk for cancer, especially in pediatric patients. Use the smallest dose necessary for imaging and ensure safe handling to protect the patient and health care worker.
Blood Glucose Abnormalities: In the oncology and neurology setting, suboptimal imaging may occur in patients with inadequately regulated blood glucose levels. In these patients, consider medical therapy and laboratory testing to ensure at least two days of normoglycemia prior to Fludeoxyglucose F 18 Injection administration.
Adverse Reactions: Hypersensitivity reactions with pruritus, edema, and rash have been reported. Have emergency resuscitation equipment and personnel immediately available.

Dosage forms and strengths

Multiple-dose 30 mL and 50 mL glass vial containing 0.74 to 7.40 GBq/mL (20 to 200 mCi/mL) Fludeoxyglucose F 18 Injection and 4.5 mg of sodium chloride with 0.1 to 0.5% w/w ethanol as a stabilizer (approximately 15 to 50 mL volume) for intravenous administration.

Fludeoxyglucose F 18 Injection is manufactured and distributed by:
PETNET Solutions, Inc.
810 Innovation Drive
Knoxville, TN 39732

These highlights do not include all the information needed to use Fludeoxyglucose F 18 Injection safely and effectively.

Download the full prescribing information for Fludeoxyglucose F 18 Injection (pdf) 0.29 MB

Our PET/CT scanners

Learn more about Molecular Imaging

Our complete portfolio

All trademarks the property of their respective owners.

Biograph Vision, Biograph Trinion, and Biograph Vision Quadra PET/CT platforms are not commercially available in all countries. Future availability cannot be guaranteed.

Based on bench testing (e.g. improved sensitivity and TOF per NEMA NU-2:2024).

Not available for Biograph Horizon RT edition.

Optional. Requires a gating device that can trigger the CT scanner (such as Anzai/RGSC). The outcomes achieved by the Siemens Healthineers customers described herein were achieved in the customer’s unique setting. Since there is no “typical” hospital and many variables exist (eg, hospital size, case mix, level of IT adoption) there can be no guarantee that others will achieve the same results.

Biograph family for radiation therapy planningSetting the standard in PET/CT for RT

Features & Benefits

Setting the standard in PET/CT for RT

AI-enabled intelligent imaging

Clinical decision making

Clinical use

Clincal image review

PET/CT-based target and organ-at-risk delineation for RTP

Our PET/CT scanners

Learn more about Molecular Imaging

Share this page:

Biograph family for
radiation therapy planningSetting the standard in PET/CT for RT